Cleveland Clinic Genomic Medicine researchers reviewed data of 19,000 patients who received colorectal cancer immunotherapy, according to a press release.
According to the Cleveland Clinic, “the results showed immune checkpoint inhibitors greatly improved survival rates for patients living with metastatic microsatellite instable (MSI-H) colorectal cancer, in line with clinical trials.” Additionally, “investigators also found certain conditions that may improve the therapy’s effectiveness against a specific type of difficult-to-treat tumor called a microsatellite stable (MSS) tumor under certain conditions, building on the initial clinical trial results.”
